Indirect comparison by network meta-analysis between bortezomib and thalidomide as first-line treatment in myeloma patients ineligible for transplantation Blood 2011, eLetter

by Dario Maratea, Fabiola Del Santo, Sabrina Trippoli, Andrea Messori

Figure 1. Network meta-analysis: comparisons between bortezomib combined with melphalan+prednisone, thalidomide combined with melphalan+prednisone, and melphalan+prednisone alone (clinical end-point = overall survival). The graph shows two direct comparisons (solid line) and one indirect comparison (dotted line). Superiority is found in the two direct comparisons vs the standard treatment as well as in the indirect head-to-head comparison between the two innovative agents. Statistical calculations were carried out using the ITC software (Ottawa, 2009)*; graph plotted as described by Fadda et al. (eBMJ, 2011**).


*URL: http://www.cadth.ca/index.php/en/itc-user-guide
**URL http://www.bmj.com/content/342/bmj.c7086.abstract/reply#bmj_el_250448